Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 16 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Follow-Up Questions
Who is the CEO of Benitec Biopharma Inc?
Dr. Jerel Banks is the Executive Chairman of the Board of Benitec Biopharma Inc, joining the firm since 2016.
What is the price performance of BNTC stock?
The current price of BNTC is $13.84, it has decreased 1.07% in the last trading day.
What are the primary business themes or industries for Benitec Biopharma Inc?
Benitec Biopharma Inc belongs to Biotechnology industry and the sector is Health Care
What is Benitec Biopharma Inc market cap?
Benitec Biopharma Inc's current market cap is $363.3M
Is Benitec Biopharma Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Benitec Biopharma Inc, including 6 strong buy, 7 buy, 1 hold, 0 sell, and 6 strong sell
